Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

5.880 +0.380 (+6.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,343
Open 5.560
Bid (Size) 5.700 (5)
Ask (Size) 5.920 (4)
Prev. Close 5.500
Today's Range 5.500 - 6.390
52wk Range 4.020 - 260.85
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Jaguar Health Reports First Quarter 2025 Financials
Via ACCESS Newswire

Performance

YTD
-78.4%
-78.4%
1 Month
+4.4%
+4.4%
3 Month
-76.5%
-76.5%
6 Month
-76.0%
-76.0%
1 Year
-97.7%
-97.7%

More News

Read More
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Via ACCESS Newswire
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Via ACCESS Newswire
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Via ACCESS Newswire
Earnings Scheduled For May 15, 2025
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
Via ACCESS Newswire
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Via ACCESS Newswire
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Via ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Top stock movements in today's session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Via ACCESS Newswire
Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
Via ACCESS Newswire
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
Via ACCESS Newswire
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESS Newswire
Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Via ACCESS Newswire
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Via ACCESS Newswire
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Via ACCESS Newswire
Jaguar Health Presenting March 27 at Emerging Growth Conference and Holding Investor Webcast March 31 Regarding Q4 2024 Financials & Near-Term Catalysts
Via ACCESS Newswire
Jaguar Health CEO, Board Members, Other C-Suite Members, and Institutional and Accredited Investors Invest in $3.448 Million Bridge Financing Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
What's going on in today's session
Via Chartmill

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?
Yes, Jaguar Health, Inc. - Common Stock is publicly traded.
What exchange does Jaguar Health, Inc. - Common Stock trade on?
Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jaguar Health, Inc. - Common Stock?
The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market
What is the current price of Jaguar Health, Inc. - Common Stock?
The current price of Jaguar Health, Inc. - Common Stock is 5.880
When was Jaguar Health, Inc. - Common Stock last traded?
The last trade of Jaguar Health, Inc. - Common Stock was at 05/16/25 04:00 PM ET
What is the market capitalization of Jaguar Health, Inc. - Common Stock?
The market capitalization of Jaguar Health, Inc. - Common Stock is 1.01B
How many shares of Jaguar Health, Inc. - Common Stock are outstanding?
Jaguar Health, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.